Criteria to qualify for study: Drug used in study:
  • Now only enrolling PTCL. Must have failed 1 prior therapy and Have 1 site of measurable disease.

HR 43

A phase 1a/1b dose escalation trial of single agent TTl-621, a novel biologic targeting CD47, in subjects with relapsed of refractory hematologic malignancies.
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory multiple myeloma or relapsed of refractory B-Cell NHL after at least 2 prior regimens.

HR 59

A phase 1a/1b open label, multicenter study evaluating the safety and pharmacokinetics of Triagolumab as a single agent and in combination with Dauratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed of refractory B-Cell Non Hodgkin Lymphoma .
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory large B-Cell Lymphoma including DLBCL, PMBCL TFL, and HGBCL; at least two systemic lines of therapy.

LYM 100

A phase ½ multicenter study evaluating the safety and efficacy of KTE-C19 In subjects with refractory aggressive Non Hodgkin Lymphoma (ZUMA-1)

Criteria to qualify for study: Drug used in study:
  • At least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody.

LYM 151

A Single-Arm, open –label phase ½ study evaluating the safety and efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR-T Cell Therapy in patients with relapsed/refractory Large B-Cell and Follicular Lymphoma.
Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory after at least 2 prior lines of therapy including rituximab and alkylating agents. Includes follicular NHL, MZL, WM, SLL

LYM 145

Efficacy and safety stuydy of Tenalisib (RP6530), a novel PI3K dual inhibitor in Patients with relapsed/refractory indolent Non-Hodgkin Lymphoma (iNHL).
Criteria to qualify for study: Drug used in study:
  • Treated with an anthracycline and anti CD20 agent; relapsed or refractory disease after at least 2 lines of therapy or autologous stem cell transplant.

LYM 146

A safety trial of Lisocabtagene Maraleucel (JCAR017) for relapsed and refractory (R/R) B-Cell Non – Hodgkin Lymphoma (NHL) in the outpatient setting.
Criteria to qualify for study: Drug used in study:
  • DLBCL, Relapsed or Refractory

LYM 120 TG Therapeutics UTX-TGR-205

A Phase 2b Randomized Study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma

Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247